Shield Therapeutics plc Financials

Market Capitalization £24.9 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-9.12
Forward PE	-0.81
Price to Sales TTM	£1.59
Price to Book MRQ	£39.47
Enterprise to Revenue	0.53
Enterprise to EBITDA	-0.14

Financial Reports as of Jun. 30, 2023

Financials

Fiscal Year Ends	2022-12-31
Most Recent Quarter	2023-06-30
Profit Margin	44.71%
Operating Margin	-266.29%
Return on Assets TTM	-42.79%
Return on Equity TTM	-146.62%

Income Statement

Revenue TTM	£5,889,346
Revenue per Share TTM	£0.02
Quarterly Revenue Growth	65.80%
Gross Profit TTM	£1,997,000
EBITDA	£-22,513,607
Net Income to Common TTM	£-38,921,584
Diluted EPS TTM	£-0.12
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	£10,823,814
Total Cash per Share MRQ	£0.02
Total Debt MRQ	£
Total Debt to Equity MRQ	21.30
Current Ratio MRQ	2.95
Book Value per Share MRQ	£0.04

Cash Flow

Operating Cash Flow TTM	£-21,946,186
Levered Free Cash Flow TTM	£-15,355,975

STX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	782,056,000
Float Shares	374,280,252
Avg 10 Volume	8,351,422
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	56.18%
% Held by Institutions	15.81%

Stock Price Summary

Beta	0.84
Fifty Two Week Low	£1.06
Fifty Two Week High	£12.85
Fifty Two Week Change	-400.00%
Day 50 MA	£1.96
Day 200 MA	£6.27

Dividends and Splits

Forward Annual Dividend Rate	£
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	£0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date